Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2015 Jun 25;35(8):1787–1797. doi: 10.1161/ATVBAHA.115.305609

Figure 4. Monocyte uptake of CE-VLDLs and subset conversion in WT and CD36−/− mice.

Figure 4

A, Representative flow cytometric analyses of monocytes that took up DiI-CE-VLDLs (becoming DiI+), from more than 5 independent experiments with at least 3 samples in each experiment. A bolus of DiI-CE-VLDLs was intravenously injected into WT mice on ND. At 3 and 24 hours, blood was taken for flow cytometric analysis. Gated total leukocytes (for CD204) or DiI+ monocytes (for CD36 and CD11c) are presented. B, Relative ratios of CD11c+CD36+ to CD11c−CD36+ monocytes in WT mice on ND after receiving repetitive daily injection of CE-VLDLs or PBS (control) for 3 days. n=4 mice/group. C, Representative flow cytometric analysis of monocyte uptake of DiI-CE-VLDLs, and quantification of DiI+ monocytes in total monocytes and DiI MFI levels on DiI+ monocytes, in WT and CD36−/− mice after receiving intravenous injection of a bolus of DiI-CE-VLDLs. n=11–12 mice/group. *P<0.05 versus preinjection (in panel B) or WT controls (in panel C).